19576528|t|Altering intensive care sedation paradigms to improve patient outcomes.
19576528|a|Providing sedation and comfort for intensive care patients has evolved in the last few years. New approaches to improving outcomes for intensive care unit (ICU) patients include providing analgesia before adding sedation and recognizing dangerous adverse effects associated with sedative medications, such as prolonged effects of midazolam, propylene glycol toxicity with lorazepam, propofol infusion syndrome, the deliriogenic effects of benzodiazepines and propofol, and bradycardia with dexmedetomidine. There are now reliable and valid ways to monitor pain and delirium in ICU patients. Dexmedetomidine reduces the incidence of delirium, reduces the duration of mechanical ventilation, and appears to be cost effective.
19576528	54	61	patient	Species	9606
19576528	122	130	patients	Species	9606
19576528	233	241	patients	Species	9606
19576528	402	411	midazolam	Chemical	MESH:D008874
19576528	413	429	propylene glycol	Chemical	MESH:D019946
19576528	430	438	toxicity	Disease	MESH:D064420
19576528	444	453	lorazepam	Chemical	MESH:D008140
19576528	455	463	propofol	Chemical	MESH:D015742
19576528	511	526	benzodiazepines	Chemical	MESH:D001569
19576528	531	539	propofol	Chemical	MESH:D015742
19576528	545	556	bradycardia	Disease	MESH:D001919
19576528	562	577	dexmedetomidine	Chemical	MESH:D020927
19576528	628	632	pain	Disease	MESH:D010146
19576528	637	645	delirium	Disease	MESH:D003693
19576528	653	661	patients	Species	9606
19576528	663	678	Dexmedetomidine	Chemical	MESH:D020927
19576528	704	712	delirium	Disease	MESH:D003693
19576528	Positive_Correlation	MESH:D020927	MESH:D001919
19576528	Negative_Correlation	MESH:D020927	MESH:D003693

